SCOPUS 정보 검색 플랫폼

Seminars in Hematology

Volumn 37, Issue 1 SUPPL. 3, 2000, Pages 22-25

Thalidomide for resistant and relapsing myeloma

(2) Alexanian, Raymond a Weber, Donna a

a UNIVERSITY OF TEXAS (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; PARAPROTEIN; THALIDOMIDE;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MYELOMA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0034019103 PISSN: 00371963 EISSN: None Source Type: Journal
DOI: 10.1016/S0037-1963(00)90079-9 Document Type: Article

Times cited : (48)

References (10)

1
- 0028775544
- The treatment of multiple myeloma
- R Alexanian M Dimopoulos The treatment of multiple myeloma N Engl J Med 330 1994 484 489
- (1994) N Engl J Med , vol.330 , pp. 484-489
- Alexanian, R¹ Dimopoulos, M²

2
- 0022655622
- High-dose glucocorticoid treatment of resistant myeloma
- R Alexanian B Barlogie D Dixon High-dose glucocorticoid treatment of resistant myeloma Ann Intern Med 105 1986 8 11
- (1986) Ann Intern Med , vol.105 , pp. 8-11
- Alexanian, R¹ Barlogie, B² Dixon, D³

3
- 0027937644
- Early myeloablative therapy for multiple myeloma
- R Alexanian M Dimopoulos J Hester Early myeloablative therapy for multiple myeloma Blood 84 1994 4278 4282
- (1994) Blood , vol.84 , pp. 4278-4282
- Alexanian, R¹ Dimopoulos, M² Hester, J³

4
- 0000783919
- Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM)
- S Singhal J Mehta P Eddlemon Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM) Blood 92 suppl 1 1998 318a abstr
- (1998) Blood , vol.92 , Issue.suppl 1 , pp. 318a
- Singhal, S¹ Mehta, J² Eddlemon, P³

5
- 84874993731
- Thalidomide is an active agent in multiple myeloma
- B Barlogie R Desikan P Eddlemon Thalidomide is an active agent in multiple myeloma Abstracts of VII International Multiple Myeloma Workshop Stockholm, Sweden 1999 47 (abstr)
- (1999) , pp. 47
- Barlogie, B¹ Desikan, R² Eddlemon, P³

6
- 0019902440
- Myeloma protein kinetics following chemotherapy
- P McLaughlin R Alexanian Myeloma protein kinetics following chemotherapy Blood 60 1982 851 855
- (1982) Blood , vol.60 , pp. 851-855
- McLaughlin, P¹ Alexanian, R²

7
- 0026656725
- Primary dexamethasone treatment of multiple myeloma
- R Alexanian M Dimopoulos K Delasalle Primary dexamethasone treatment of multiple myeloma Blood 80 1992 887 890
- (1992) Blood , vol.80 , pp. 887-890
- Alexanian, R¹ Dimopoulos, M² Delasalle, K³

8
- 0033134764
- Bone marrow neovascularizarion, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
- A Vacca D Ribatti M Presta Bone marrow neovascularizarion, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma Blood 93 1999 3064 3073
- (1999) Blood , vol.93 , pp. 3064-3073
- Vacca, A¹ Ribatti, D² Presta, M³

9
- 0030053014
- Whither interferon for myeloma and other hematologic malignancies?
- R Alexanian D Weber Whither interferon for myeloma and other hematologic malignancies? Ann Intern Med 124 1996 264 265
- (1996) Ann Intern Med , vol.124 , pp. 264-265
- Alexanian, R¹ Weber, D²

10
- 0027447339
- A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: A Cancer and Leukemia Group B study
- MR Cooper K Dear OR McIntyre A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: A Cancer and Leukemia Group B study J Clin Oncol 11 1993 155 160
- (1993) J Clin Oncol , vol.11 , pp. 155-160
- Cooper, MR¹ Dear, K² McIntyre, OR³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.